recap buy thesi intact solid growth
rais pt post strong result includ continu upbeat outlook
organ growth led biopharma china highlight
increas full year guidanc potenti conserv given doesnt incorpor
budget flush occur last year valuat expand
materi recent year see justifi given higher level organ
growth driven numer secular factor addit leverag lowest level
year afford ampl b/ capac part growth
come concern center growth flatten china industri
slowdown/risk expect organ growth even adjust
benefit recaptur acceler stack biopharma
grew ldd broad base led robust bioproduct academ
steadi msd hc/dx quit strong hsd industrial/appli flat cite
comp industri portion total revenu declin china anoth
healthi demand europ grew hsd sever peer seen weak demand
broad base steadi ebit slight miss strong revenu enabl ep beat
full year revenu ep guidanc rais organ growth
impli organ read through hard draw much direct read across
given size scale share gain consist perform strong bioproduct
posit pharma result clear read across cite
share gain chroma mass spec struggl late mix
weak industri ideal industri orient peer though compani
mix differ tough comp china eu result posit
valuat rais pt
pt base upon ntm price-to-earnings increas given
modestli higher forecast plu roll forward one quarter dcf support pt
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price oct edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
million us except per share amount
good
interest expens incom
net incom continu op
million us except per share amount
good
interest expens incom
net incom continu op
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
pt base upon ntm price-to-earnings given modestli higher forecast plu
roll forward one quarter dcf support pt
industry-wid risk includ declin spend pharmaceut compani
due signific declin fund small compani promin
trial failur affect class drug deceler global growth
includ risk escal trade tension pressur academ
govern budget could result recessionari cost-cut
polit chang price pressur diagnost sector due
protect access medicar act pama chang competit dynam
includ disrupt new entrant certain technolog inabl
compani compet effect china critic growth market foreign
exchang fluctuat chang tax polici
risk
includ biopharma slow chines economi
integr recent larg make bad strateg decis futur
